Abstract
Background: Xylometazoline, a sympathomimetic agent, is considered safe in hypertensive patients as a relief measure for nasal congestion with intranasal application.
Case Report: In the present case, a 58-year old male patient, having ischemic heart disease, controlled hypertension on telmisartan and bisoprolol, experienced hypertensive urgency in a span of two hours of intranasal administration of the paediatric formulation of xylometazoline.
Conclusion: The interaction with bisoprolol should be kept in mind while using xylometazoline.
Keywords: Xylometazoline, sympathomimetic agent, bisoprolol, interaction, hypertensive urgency, intranasal.
Graphical Abstract
Current Drug Safety
Title:Use of Paediatric Xylometazoline Nasal Drop is not a Child’s Play in Hypertensive Patients on Bisoprolol: A Case Report
Volume: 16 Issue: 3
Author(s): Hira Bhalla*, Abhishek Gupta and Tejas Patel
Affiliation:
- Department of Pharmacology and Therapeutics, All India Institute of Medical Sciences Gorakhpur, Gorakhpur,India
Keywords: Xylometazoline, sympathomimetic agent, bisoprolol, interaction, hypertensive urgency, intranasal.
Abstract:
Background: Xylometazoline, a sympathomimetic agent, is considered safe in hypertensive patients as a relief measure for nasal congestion with intranasal application.
Case Report: In the present case, a 58-year old male patient, having ischemic heart disease, controlled hypertension on telmisartan and bisoprolol, experienced hypertensive urgency in a span of two hours of intranasal administration of the paediatric formulation of xylometazoline.
Conclusion: The interaction with bisoprolol should be kept in mind while using xylometazoline.
Export Options
About this article
Cite this article as:
Bhalla Hira *, Gupta Abhishek and Patel Tejas , Use of Paediatric Xylometazoline Nasal Drop is not a Child’s Play in Hypertensive Patients on Bisoprolol: A Case Report, Current Drug Safety 2021; 16 (3) . https://dx.doi.org/10.2174/1574886316666210114094856
DOI https://dx.doi.org/10.2174/1574886316666210114094856 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Evolution of Antipsychotic Intervention in the Schizophrenic Psychosis
Current Drug Targets Neurocognitive Monitoring and Care During Pediatric Cardiopulmonary Bypass — Current and Future Directions
Current Cardiology Reviews Central Nervous System Circuitry and Peripheral Neural Sympathetic Activity Responsible for Essential Hypertension
Current Neurovascular Research Steroids and Vasopressor-Resistant Hypotension in Preterm Infants
Current Pediatric Reviews RAAS Inhibition and Renal Protection
Current Pharmaceutical Design Meet Our Editorial Board Member
Current Pharmaceutical Biotechnology Benefits of SGLT2 Inhibitors Beyond Glycemic Control – A Focus on Metabolic, Cardiovascular and Renal Outcomes
Current Diabetes Reviews New Indications for Corticosteroids in Intensive Care Units
Current Drug Targets Liposomal-All-trans-Retinoic Acid in the Treatment of Acute Promyelocytic Leukemia
Current Cancer Therapy Reviews Organic Lesions in the Brain MRI of Children with Febrile Seizure
Current Medical Imaging Rac-1 as a New Therapeutic Target in Cerebro- and Cardio-Vascular Diseases
Current Drug Targets Circulating Biochemical Markers of Brain Damage in Infants Complicated by Ischemia Reperfusion Injury
Cardiovascular & Hematological Agents in Medicinal Chemistry Critical Illness in Obstetric Patients: Venous Thromboembolism in Pregnancy
Current Women`s Health Reviews Discovery and ADMET: Where Are We Now
Current Topics in Medicinal Chemistry The Possible Therapeutic Actions of Peroxisome Proliferator-Activated Receptor α(PPARα) Agonists,PPARγ Agonists,3-Hydroxy-3- Methylglutaryl Coenzyme A (HMG-CoA)Reductase Inhibitors,Angiotensin Converting Enzyme (ACE)Inhibitors and Calcium (Ca)-Antagonists on Vascular Endothelial Cells
Current Drug Targets - Cardiovascular & Hematological Disorders Melatonin Receptor Agonist Agomelatine: A New Drug for Treating Unipolar Depression
Current Pharmaceutical Design Targeting Malignancies with Disulfiram (Antabuse): Multidrug Resistance, Angiogenesis, and Proteasome
Current Cancer Drug Targets A Practical Comprehensive Approach to Management of Acute Decompensated Heart Failure
Current Cardiology Reviews Stent-Based Delivered Anti-Proliferative Drugs in the Prevention of Coronary Stent Restenosis
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Perioperative Management of Hyperlipidemia Medications
Current Clinical Pharmacology